ZVS101e

DRUG5 trials

Sponsors

Peking University Third Hospital, Chigenovo Co., Ltd

Conditions

Bietti Crystalline Corneoretinal DystrophyBietti Crystalline DystrophyBietti's Crystalline Dystrophy

Early Phase 1

Safety and Tolerability of ZVS101e in Patients With Bietti 's Crystalline Dystrophy

Peking University Third HospitalBietti's Crystalline Dystrophy

Start: 2022-09-23End: 2025-03-31Target: 6Updated: 2023-02-06

Phase 1

Safety and Efficacy of ZVS101e in Patients With Bietti 's Crystalline Dystrophy

Active, not recruitingNCT05832684

Chigenovo Co., LtdBietti's Crystalline Dystrophy

Start: 2023-02-20End: 2028-12-01Target: 24Updated: 2026-06-17

Phase 3

Efficacy and Safety of ZVS101e in Patients With Bietti 's Crystalline Dystrophy

Active, not recruitingNCT06743646

Chigenovo Co., LtdBietti Crystalline Corneoretinal Dystrophy, Bietti Crystalline Dystrophy

Start: 2024-12-27End: 2030-06-30Target: 62Updated: 2026-06-17

Unknown Phase

Compassionate Administration of ZVS101e for Extended Treatment

Enrolling by invitationNCT07307469

Chigenovo Co., LtdBietti Crystalline Corneoretinal Dystrophy

Start: 2026-07-01End: 2027-07-01Target: 32Updated: 2026-06-17

ZVS101e in Patients With Bietti's Crystalline Dystrophy

Not yet recruitingNCT07653971

Chigenovo Co., LtdBietti Crystalline Corneoretinal Dystrophy, Bietti's Crystalline Dystrophy

Start: 2026-09-30End: 2035-12-01Target: 300Updated: 2026-08-24

Related Papers

Gene therapy for Bietti crystalline corneoretinal dystrophy: A phase 1/2 clinical trial.

2026-01-10